Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine the tumor response rate of NOV-002 plus carboplatin
in a cohort of women with platinum resistant cancer of ovarian origin.
Phase:
Phase 2
Details
Lead Sponsor:
Cellectar Biosciences, Inc.
Collaborators:
Dana-Farber Cancer Institute Massachusetts General Hospital